REPL
Replimune Group, Inc.
Next earnings Aug 5, 2026 · consensus $-0.64 EPS, $536K rev
Last earnings +5.8% on 2026-02-03
$11.63
▲ +4.49%$11.63▲ +26.00%
over 1Y
L $1.70EODHDH $12.63
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.5%
1W+4.0%
1M+147.4%
3M+61.1%
YTD+30.7%
1Y+26.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Hold
Pre-revenue oncolytic biotech burning ~$192M/yr with ~$111M cash — funding cliff and dilution overwhelm any pipeline optionality at $11.39.
Net income -$247M · FY2025
Replimune is a clinical-stage oncolytic immunotherapy company that, per its own 10-K, has 'not generated any revenue from product sales' and explicitly warns it 'expect[s] to continue to incur significant expenses and increasing operating losses for at least the next several years.' The financial profile confirms this: FY2025 net loss widened to -$247M (from -$216M), operating cash burn ran -$192M, and the accumulated deficit ballooned to -$949M. R&D alone consumed $189M against zero revenue — the entire enterprise is a binary bet on the proprietary RPx platform clearing regulatory and clinical hurdles that the filing does not claim are near.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$80.0M | -$118M | -$177M | -$235M | -$262M |
| Net income | -$80.9M | -$118M | -$174M | -$216M | -$247M |
| Diluted EPS | -$1.75 | -$2.26 | -$2.99 | -$3.24 | -$3.07 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$832M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-27.6%
FCF yield-22.2%
Quality & risk
ROIC (est.)-44.7%
Free cash flow-$199M
Total debt$46.4M
Net cash$64.7M
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+25.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Reg FD disclosure2026-06-26
- 8-K Reg FD disclosure2026-05-29
Reg FD investor/scientific presentation update; no new financial disclosure
- 8-K Reg FD disclosure2026-04-13
Reg FD + other event disclosure, likely clinical/regulatory program update
- 8-K Material agreement2026-02-03
Q3 FY26 results filed; ongoing cash burn funding RP1/RP2 clinical work
- 10-Q Quarterly report2026-02-03
Q3 FY26 results filed; ongoing cash burn funding RP1/RP2 clinical work
- 8-K Reg FD disclosure2026-01-12
Reg FD presentation, likely conference/pipeline update
- 8-K Earnings results2025-11-06
Q2 FY26 results filed; losses continue with R&D-led spend
- S-3/A Shelf registration (potential raise)2025-11-06
Q2 FY26 results filed; losses continue with R&D-led spend
- 10-Q Quarterly report2025-11-06
Q2 FY26 results filed; losses continue with R&D-led spend
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-262026-06-26open ↗4Period ending 2026-06-012026-06-03open ↗8-KPeriod ending 2026-05-292026-05-29open ↗SCHEDULE 13GFiling2026-05-21open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-12open ↗
Frequently asked
- Is Replimune Group, Inc. (REPL) a buy?
- REPL currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue oncolytic biotech burning ~$192M/yr with ~$111M cash — funding cliff and dilution overwhelm any pipeline optionality at $11.39.
- What is Replimune Group, Inc.'s quality score?
- REPL scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001737953, latest 10-Q filed 2026-02-03) · EODHD · analysis by claude-code · as of 6/25/2026, 2:36:07 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.